PythiaAI Revolutionizes Biotech R&D with StableBody and Quine Biologics Partnership

20/15 Visioneers

HEREFORD, PA — StableBody Technologies and Quine Biologics have integrated the PythiaAI™ framework from 20/15 Visioneers, marking a transformative step in antibody design and protein engineering. This cutting-edge Large Language Model (LLM) Agentic Framework is poised to accelerate research and development across multiple scientific fields, including drug discovery and materials science.

The adoption of PythiaAI™ enhances StableBody’s computational systems, which are crucial for predicting protein stability and affinity. Harry Horn, CEO of StableBody Technologies, noted, “With PythiaAI™, we are now able to rapidly discover new hypotheses for protein stability, both in our experiments and in literature. This addition has immediately solved the problem of searching the universe for new optimized proteins.”

Quine Biologics has also integrated PythiaAI™ into its Bespoke-A.B. design platform. This innovation streamlines antibody design, covering stages from hypothesis generation to validation. Dr. Brett Spurrier, founder of Quine Biologics, stated, “By integrating PythiaAI™ into our Bespoke-A.B. design platform, we’re able to leverage the advanced capabilities of LLMs to streamline the process of antibody design, from hypothesis generation to validation. This collaboration empowers us to enhance the stability and efficacy of our therapeutic antibodies more efficiently than ever before, pushing the boundaries of what’s possible in protein engineering.”

PythiaAI™, developed by the AI & GenAI Practice at 20/15 Visioneers, is a versatile framework that uses agents to interface with LLMs and traditional software, autonomously enhancing scientific reasoning and database mediation. The framework provides vital insights into R&D workflows, making it an invaluable tool for biotech professionals.

Dr. Raminderpal Singh, Global Head of AI & GenAI Practice at 20/15 Visioneers, highlighted the framework’s benefits, saying, “PythiaAI™ is a future-proof low-cost framework for R&D teams to take advantage of the power of LLMs. With StableBody Technologies and Quine Biologics, we have demonstrated its augmenting value and strengths in protein engineering.”

READ:  ITAG Announces TECH360 Annual Technology Conference to Provide Essential Insights in Today’s Data-Driven World November 14 at Penn State University – Great Valley

By adopting PythiaAI™, StableBody and Quine Biologics are not only enhancing their research capabilities but also maintaining a competitive edge in biotechnology. This collaboration underscores the profound impact of AI-driven frameworks on advancing scientific discovery and development.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.